Glioblastoma Clinical Trials

75 studies are recruiting for glioblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

   The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   18 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06333899 on ClinicalTrials.gov

2. Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

   This study evaluates how useful and acceptable the components of the "Couples Coping Together Against Cancer", referred to as "The Program", are to the participants with cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07664579 on ClinicalTrials.gov

3. A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

   RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California

   Locations

   3 in total

   Run by

   RasCal Therapeutics, Inc.

   See if you can join NCT04678648 on ClinicalTrials.gov

4. Imaging Acetadote Metabolism in Glioblastoma

   This goal of this clinical trial is to evaluate how Acetadote affects metabolism in patients with glioblastoma. Drugs like Acetadote, which affect the level of damage in a cell (oxidative stress), may impact brain tumor metabolism and slow the growth of brain tumors. The investigators are evaluatin…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT07387666 on ClinicalTrials.gov

5. Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

   This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT07392957 on ClinicalTrials.gov

6. Sitagliptin in Recurrent/Progressive Grade 4 Glioma

   Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa Health Care, Iowa City, Iowa

   Run by

   Kailin Yang, MD, PhD

   See if you can join NCT07541781 on ClinicalTrials.gov

7. ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

   This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compo…

   Stage

   Phase 1

   Ages

   2 to 21

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   7 in total

   Run by

   Sabine Mueller, MD, PhD

   See if you can join NCT04732065 on ClinicalTrials.gov

8. Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

   A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UK Markey Cancer Center, Lexington, Kentucky

   Locations

   8 in total

   Run by

   Orano Med Theranostics, SAS

   See if you can join NCT05283330 on ClinicalTrials.gov

9. The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer

   Precision oncology has led to a growing population of adults with advanced cancer living increasingly longer lives in the face of profound uncertainty about the future, with over half reporting moderate to high fear of cancer progression (FoP). These fears are associated with anxiety and depression…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Colorado Anschutz Medical Campus, Aurora, Colorado

   Locations

   2 in total

   Run by

   University of Colorado, Boulder

   See if you can join NCT07636200 on ClinicalTrials.gov

10. Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

    Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT02861898 on ClinicalTrials.gov

11. Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

    The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherap…

    Stage

    Phase 1

    Ages

    18 to 74

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT03213002 on ClinicalTrials.gov

12. Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

    Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05271240 on ClinicalTrials.gov

13. Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

    This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05954858 on ClinicalTrials.gov

14. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

    This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05979064 on ClinicalTrials.gov

15. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

    The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

    Stage

    Phase 2

    Ages

    1 to 39

    Site

    Children's National Medical Center, Washington D.C., District of Columbia

    Locations

    20 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05843253 on ClinicalTrials.gov

16. Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

    Preclinical data have demonstrated the combination of azeliragon, a RAGE inhibitor, with radiation therapy (RT) can effectively reduce immune-suppressive myeloid cells and restore T-cell activation to improve tumor control in murine glioma models. Ongoing clinical studies of azeliragon with RT alon…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06831526 on ClinicalTrials.gov

17. IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

    This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Florida Health, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT05353530 on ClinicalTrials.gov

18. Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

    This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05281731 on ClinicalTrials.gov

19. LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

    The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Maryland Proton Treatment Center, Baltimore, Maryland

    Locations

    5 in total

    Run by

    University of Maryland, Baltimore

    See if you can join NCT04699773 on ClinicalTrials.gov

20. PH Sensitive MRI Based Resections of Glioblastoma

    Current standard of care therapy and all FDA approved adjuvant therapy for glioblastoma continue to provide less than 12 months of progression free survival (PFS) and less than 24 months of overall survival (OS). There is an extreme need for any novel therapy against glioblastoma that increases pro…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ronald Reagan Medical Center, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT06176066 on ClinicalTrials.gov

21. First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

    This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievabl…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Elizabeth C. Neil, MD, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07560865 on ClinicalTrials.gov

22. ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma

    The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT05917145 on ClinicalTrials.gov

23. Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

    Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT02800486 on ClinicalTrials.gov

24. HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

    Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Houston Methodist Neurological Institute, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT03603405 on ClinicalTrials.gov

25. Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

    This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI), and ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT07461948 on ClinicalTrials.gov